Sidoti Csr Weighs in on Balchem Co.’s Q3 2024 Earnings (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Analysts at Sidoti Csr cut their Q3 2024 earnings per share (EPS) estimates for Balchem in a note issued to investors on Monday, May 6th. Sidoti Csr analyst K. May now expects that the basic materials company will earn $1.04 per share for the quarter, down from their prior forecast of $1.06. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. Sidoti Csr also issued estimates for Balchem’s Q4 2024 earnings at $0.95 EPS, FY2024 earnings at $4.00 EPS, Q1 2025 earnings at $1.03 EPS, Q2 2025 earnings at $0.99 EPS, Q3 2025 earnings at $1.05 EPS and Q4 2025 earnings at $1.05 EPS.

Several other research analysts have also issued reports on BCPC. HC Wainwright lifted their price target on shares of Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday. StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Stock Performance

Shares of BCPC opened at $155.48 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.61 and a quick ratio of 1.72. The firm’s 50 day moving average is $151.00 and its 200-day moving average is $141.21. Balchem has a 12-month low of $110.74 and a 12-month high of $159.52. The stock has a market capitalization of $5.04 billion, a P/E ratio of 43.92, a P/E/G ratio of 3.33 and a beta of 0.72.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The business had revenue of $228.70 million during the quarter, compared to analyst estimates of $234.66 million. During the same quarter in the prior year, the firm posted $0.66 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis.

Insider Buying and Selling

In other Balchem news, SVP Michael Robert Sestrick sold 11,100 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the sale, the senior vice president now directly owns 6,736 shares of the company’s stock, valued at approximately $1,032,022.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Balchem news, SVP Michael Robert Sestrick sold 11,100 shares of Balchem stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the transaction, the senior vice president now owns 6,736 shares of the company’s stock, valued at approximately $1,032,022.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO William A. Backus sold 9,180 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $156.37, for a total value of $1,435,476.60. Following the completion of the transaction, the chief accounting officer now owns 12,914 shares in the company, valued at approximately $2,019,362.18. The disclosure for this sale can be found here. In the last 90 days, insiders sold 76,630 shares of company stock valued at $11,843,249. Company insiders own 1.77% of the company’s stock.

Institutional Investors Weigh In On Balchem

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCPC. GAMMA Investing LLC increased its stake in shares of Balchem by 18.0% in the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after acquiring an additional 72 shares during the last quarter. Cardinal Capital Management grew its stake in Balchem by 0.4% in the fourth quarter. Cardinal Capital Management now owns 19,539 shares of the basic materials company’s stock valued at $2,922,000 after purchasing an additional 79 shares in the last quarter. Signaturefd LLC increased its position in Balchem by 123.0% in the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after purchasing an additional 91 shares during the last quarter. SageView Advisory Group LLC raised its stake in shares of Balchem by 2.1% during the 3rd quarter. SageView Advisory Group LLC now owns 4,814 shares of the basic materials company’s stock worth $597,000 after purchasing an additional 98 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Balchem by 0.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 14,532 shares of the basic materials company’s stock valued at $1,803,000 after buying an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.